


# Meta-analyses of results from randomized outcome trials comparing cardiovascular effects of SGLT2i and GLP-1RA in Asian vs. White patients with and without type 2 diabetes

## SUPPLEMENTARY DATA

### Supplementary Figure S1 – PRISMA diagram



CV, cardiovascular; GLP-1RA, glucagon-like peptide-1 receptor agonist; HHF, hospitalization for heart failure; HR, hazard ratio; MACE, major adverse cardiovascular event; SGLT2i, sodium-glucose co-transporter 2 inhibitor.

## Supplementary Figure S2 – Risk of Bias assessment

		Risk of bias domains					
		D1	D2	D3	D4	D5	Overall
Study	EMPA-REG OUTCOME						
	CANVAS Program						
	VERTIS CV						
	SCORED						
	Dapa-HF						
	EMPEROR-Reduced						
	LEADER						
	SUSTAIN-6						
	EXSCEL						
	HARMONY OUTCOMES						
	REWIND						
	PIONEER 6						

Domains:  
D1: Bias arising from the randomization process.  
D2: Bias due to deviations from intended intervention.  
D3: Bias due to missing outcome data.  
D4: Bias in measurement of the outcome.  
D5: Bias in selection of the reported result.

Judgement  
 Low

Risk of bias was assessed using version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2).